Variation in drug response related to polymorphisms in the β2-adrenergic receptor
US6861217B1 · kind B1 · utility
8Cited by
7References
2Claims
0Family size
Assignees
Inventor
Key dates
| Filing date | Nov 24, 1999 |
| Grant date | Mar 1, 2005 |
| Priority date | — |
| Expiry date | Nov 24, 2019 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/156
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
A novel polymorphic site in the 5′ leader cistron of the β2-adrenergic receptor (β2AR) gene is disclosed. The polymorphisms present at this site result in different levels of inhibition of translation of β2AR mRNA. Compositions and methods for genotyping this polymorphic site as disclosed. In addition, methods for using this genotype information are disclosed, including predicting genetic predisposition to a disease modified by β2AR expression and predicting a patient's bronchodilating response to β2-agonists.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.